Claims

1. Use of a human anti-inflammatory peptide in the manufacture of a medicament for prophylaxis or treatment of an inflammatory pulmonary disease by inhalatory administration, wherein
an aerosol comprising solid particles or liquid droplets containing the anti-inflammatory peptide is to be administered to a subject having the inflammatory pulmonary disease;
the anti-inflammatory peptide is aviptadil; and
the inflammatory pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease, asthma, sarcoidosis of the lung, cystic fibrosis, bronchiectasis, adult respiratory distress syndrome, pulmonary fibrosis, chronic lung allograft dysfunction, pulmonary edema, lung ischemia reperfusion injury and primary graft dysfunction after lung transplantation.

2. The use according to claim 1, wherein a mesh nebulizer releases the aerosol for the inhalatory administration.

3. The use according to claim 2, wherein said mesh nebulizer is a vibrating mesh nebulizer, and wherein a vibration frequency of the vibrating mesh nebulizer is in the range of 80 kHz to 200 kHz.

4. An aerosol for use in the prophylaxis or treatment of an inflammatory pulmonary disease, comprising
liquid droplets comprising a human anti-inflammatory peptide, wherein:
the anti-inflammatory peptide is aviptadil, and
the inflammatory pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease, asthma, sarcoidosis of the lung, cystic fibrosis, bronchiectasis, adult respiratory distress syndrome, pulmonary fibrosis, chronic lung allograft dysfunction, pulmonary edema, lung ischemia reperfusion injury and primary graft dysfunction after lung transplantation.

5. A kit for use in the prophylaxis or treatment of an inflammatory pulmonary disease, the kit comprising a mesh nebulizer and a pharmaceutically acceptable container with a pharmaceutical formulation to produce the aerosol of claim 4.

6. The kit of claim 5 further comprising a mouthpiece for inhalation fitting to said mesh nebulizer.

7. The aerosol of claim 4, wherein the aerosol comprises from about 20 µg/mL to about 200 µg aviptadil/mL aerosol.

8. The aerosol of claim 4 or 7, wherein the aerosol comprises from about 35 µg/mL to about 140 µg aviptadil/mL aerosol.

9. The use according to any one of claim 1, 2, or 3, wherein a daily dose of aviptadil is from about 100 µg to about 1000 µg.

10. The use according to claim 9, wherein the daily dose is to be provided in 1 to 10 portions.

11. The use according to claim 9, wherein the daily dose is to be provided in 2 to 6 portions.

12. The aerosol of claim 4 or 7, wherein the aerosol is to be administered to provide a daily dose of aviptadil from about 100 µg to about 1000 µg.

13. The use of claim 12, wherein the daily dose is to be provided in 1 to 10 portions.

14. The use of claim 12, wherein the daily dose is to be provided in 2 to 6 portions.